Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of CS1003 in solid tumor patients in USA

Trial Profile

A clinical study of CS1003 in solid tumor patients in USA

Planning
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs CS-1003 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Oct 2018 New trial record
    • 23 Oct 2018 According to a CStone Pharmaceuticals media release, the US FDA has granted approval to the company's Investigational New Drug (IND) application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top